Pemigatinib improved PFS as first-line therapy for FGFR2-rearranged cholangiocarcinoma in the phase 3 FIGHT-302 trial.
Emerging Data Advancing Precision Medicine Across GI Malignancies From ASCO 2026
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5